A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma.
作者信息
Hönemann Dirk, Prince H Miles, Seymour John F, Wolf Max M, Westerman David, Januszewicz E Henry
出版信息
Leuk Lymphoma. 2005 Jun;46(6):945-7. doi: 10.1080/10428190500057684.
PMID:16019544
Abstract
摘要
相似文献
1
A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma.
Leuk Lymphoma. 2005 Jun;46(6):945-7. doi: 10.1080/10428190500057684.
2
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.聚乙二醇化脂质体阿霉素、长春新碱和低剂量地塞米松联合治疗新诊断多发性骨髓瘤患者的II期试验。
Cancer. 2002 Nov 15;95(10):2160-8. doi: 10.1002/cncr.10946.
3
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.硼替佐米联合地塞米松优于长春新碱联合多柔比星联合地塞米松作为新诊断多发性骨髓瘤患者自体造血干细胞移植前的诱导治疗：IFM 2005-01 期 III 期试验结果。
J Clin Oncol. 2010 Oct 20;28(30):4621-9. doi: 10.1200/JCO.2009.27.9158. Epub 2010 Sep 7.
4
Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma.聚乙二醇化脂质体阿霉素/长春新碱/地塞米松与阿霉素/长春新碱/地塞米松治疗新诊断多发性骨髓瘤患者的临床疗效及经济分析
Clin Lymphoma Myeloma. 2007 Apr;7 Suppl 4:S150-5. doi: 10.3816/clm.2007.s.016.
5
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.聚乙二醇化脂质体阿霉素、长春新碱和地塞米松与阿霉素、长春新碱和地塞米松相比，可显著降低新诊断的多发性骨髓瘤患者的毒性：一项III期多中心随机试验。
Cancer. 2006 Feb 15;106(4):848-58. doi: 10.1002/cncr.21662.
6
Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
Nat Clin Pract Oncol. 2008 Feb;5(2):70-1. doi: 10.1038/ncponc1005. Epub 2007 Nov 6.
7
Hematology: Thalidomide maintenance in multiple myeloma.
Nat Rev Clin Oncol. 2009 Oct;6(10):565-6. doi: 10.1038/nrclinonc.2009.131.
8
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.多柔比星脂质体联合长春新碱和地塞米松（VAD）静脉推注与普通多柔比星联合长春新碱和地塞米松（VAD）作为多发性骨髓瘤一线治疗的前瞻性随机对照研究
Ann Oncol. 2003 Jul;14(7):1039-44. doi: 10.1093/annonc/mdg287.
9
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.骨髓瘤诱导治疗的移植后结局：沙利度胺与地塞米松对比多柔比星、长春新碱及地塞米松用于高剂量美法仑联合自体干细胞支持治疗之前
Am J Hematol. 2007 Dec;82(12):1071-5. doi: 10.1002/ajh.21038.
10
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.三氧化二砷联合脂质体阿霉素、长春新碱和地塞米松用于新诊断多发性骨髓瘤的II期临床试验。
Leuk Res. 2008 Aug;32(8):1295-8. doi: 10.1016/j.leukres.2007.10.020. Epub 2007 Dec 21.
Zotero 插件